iTeos Therapeutics Stock Surges On $2.1B Development Pact For EOS-448 With GSK
iTeos Therapeutics (NASDAQ:ITOS) and GlaxoSmithKline plc (NYSE:GSK) have agreed to co-develop and co-commercialize EOS-448, an anti-TIGIT monoclonal antibody. Under the terms of…
Earnings Scheduled For May 13, 2021
Companies Reporting Before The Bell
• CASI Pharmaceuticals (NASDAQ:CASI) is estimated to report quarterly loss at $0.06 per share on revenue of $5.05 million.